Alnylam Pharmaceuticals (NASDAQ: ALNY)
Key Data Points
Alnylam Pharmaceuticals Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Alnylam Pharmaceuticals Company Info
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
News & Analysis
Alnylam Delivers a Big Q4 Earnings Beat
Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.
Alnylam's Revenues Drop Sharply in Q3
Alnylam Pharmaceuticals' product revenues grew at a healthy pace, but on other fronts, it struggled.
Alnylam Pharmaceuticals Outperformed in Q1
The rare disease specialist beat Wall Street's expectations with strong revenue growth and smaller-than-anticipated losses.
Why Alnylam Pharmaceuticals Stock Is Sinking Today
Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.
2 Growth Stocks That Could Rocket Higher Before the End of 2023
Potential approvals of new medicines expected soon could push these stocks through the roof.
Why Alnylam Pharmaceuticals Topped the Market Today
Monday was a good day for biotechs fighting the good fight against a common degenerative brain disorder.
3 Biopharmas on Buyout Watch
These three biotech companies could be headed for a buyout soon.
Is This Unknown Growth Stock a Buy After Its Blast Off?
It's pursuing a smart and tightly focused drug development strategy that could pay off big.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.